CRISPR - search results
If you're not happy with the results, please do another search
One and Done? How CRISPR Is Changing the Clinical Outlook for Multiple Diseases
Despite barriers that still need to be overcome, it is clear that recent and future developments in gene editing technology could genuinely change lives. Rapid progress suggests that 2023 will likely be a big year for gene editing in terms of clinical success.
SNIPR Biome Reports Good Initial “In-Human” Results for CRISPR Gene Therapy
SNIPR Biome achieves good interim Phase I results in a trial to combat antibiotic resistant E. coli in blood cancer patients.
CRISPR-Cas Used against Antimicrobial Resistance
The CRISPR-Cas gene editing system is being used in laboratory studies to block antimicrobial resistance. The work is being done by by researchers at the University of Exeter and the Institute of Hydrobiology in Dresden.
Function Oncology Launches with CRISPR-Powered Personalized Functional Genomics Platform
Function Oncology has officially launched with the goal of revolutionizing the future of targeted cancer treatment by developing a CRISPR-powered, personalized functional genomics platform.
Health System Launches CRISPR-Based Biopharma
ChristianaCare announced today that it has spun out CorriXR Therapeutics, a biotechnology company that will leverage CRISPR gene editing technology to develop oncology therapeutics.
Role of Mucins in SARS-CoV-2 Infection Probed via CRISPR
A CRISPR screen showed certain mucins are protective against SARS-CoV-2 and that expression levels of these proteins can impact disease progression.
CRISPR Pioneer Stanley Qi’s Epic Bio Launches with $55 Million
Epic Bio has launched with a $55 million Series A financing. It was founded by Stanley Qi, Ph.D., a co-inventor on the University of California's CRISPR patent and will use epigenetics to create a new class of genetic medicines.
CRISPR-, Macrophage-Focused DEM BioPharma Launches with $70M Financing
The company’s focus is to create new therapies that leverage macrophages and other myeloid effector cells to eliminate tumors by targeting novel “don’t eat me” (DEM) and “eat me (EM) signals on cancer cells and macrophages.
The Evolution of CRISPR Technology from Editing to Diagnostics
The discovery of these new Cas enzymes really catalyzed researchers to investigate how CRISPR technology could be used in diagnostics and over the last few years several biotech companies have been set up to explore this potential.
Novel CRISPRi-Based Screen Could Improve Drug-Resistant TB Treatment
A new CRISPR interference-based chemical and genetic screen could guide future tuberculosis treatment and new drug development.